Post ASH speaker abstracts 2019

HODGKIN LYMPHOMA

 

Abstracts selected by Wendy Osborne (NCCC, Newcastle)

Abstract 925
PET-Guided Treatment of Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase 3 Trial HD16 By the German Hodgkin Study Group

Abstract (PDF)

 

Abstract 926
B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG)

Abstract (PDF)

 

Abstract 929
Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach

Abstract (PDF)

 

Abstract 928
Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

Abstract (PDF)

 

Abstract 930
Relapse Risk and Loss in Expectation of Lifetime in Young Classical Hodgkin Lymphoma Patients – a Nordic Lymphoma Group Study of 2,582 Patients

Abstract (PDF)